CN116139271A - Preparation method of transition metal nano enzyme with fluorescence and application of transition metal nano enzyme in improving intestinal health - Google Patents
Preparation method of transition metal nano enzyme with fluorescence and application of transition metal nano enzyme in improving intestinal health Download PDFInfo
- Publication number
- CN116139271A CN116139271A CN202310083669.0A CN202310083669A CN116139271A CN 116139271 A CN116139271 A CN 116139271A CN 202310083669 A CN202310083669 A CN 202310083669A CN 116139271 A CN116139271 A CN 116139271A
- Authority
- CN
- China
- Prior art keywords
- enzyme
- transition metal
- metal nano
- fluorescence
- reaction kettle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052723 transition metal Inorganic materials 0.000 title claims abstract description 27
- 150000003624 transition metals Chemical class 0.000 title claims abstract description 25
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 24
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000007413 intestinal health Effects 0.000 title claims abstract description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 14
- 229960003180 glutathione Drugs 0.000 claims abstract description 12
- 108010024636 Glutathione Proteins 0.000 claims abstract description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 8
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 claims abstract description 6
- 239000011609 ammonium molybdate Substances 0.000 claims abstract description 6
- 235000018660 ammonium molybdate Nutrition 0.000 claims abstract description 6
- 229940010552 ammonium molybdate Drugs 0.000 claims abstract description 6
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 6
- 239000011781 sodium selenite Substances 0.000 claims abstract description 6
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 238000001291 vacuum drying Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 239000008367 deionised water Substances 0.000 claims abstract description 4
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000007789 sealing Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract description 3
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 102000016938 Catalase Human genes 0.000 abstract description 6
- 108010053835 Catalase Proteins 0.000 abstract description 6
- 238000002965 ELISA Methods 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000005284 excitation Effects 0.000 abstract description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 2
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 2
- 238000001027 hydrothermal synthesis Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 14
- 210000001072 colon Anatomy 0.000 description 14
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000004580 weight loss Effects 0.000 description 10
- 206010009900 Colitis ulcerative Diseases 0.000 description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229910052750 molybdenum Inorganic materials 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- -1 transition metal chalcogenide Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002789 catalaselike Effects 0.000 description 2
- 150000004770 chalcogenides Chemical class 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229910021389 graphene Inorganic materials 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100030393 G-patch domain and KOW motifs-containing protein Human genes 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001200 fecal consistency Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910052982 molybdenum disulfide Inorganic materials 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002064 nanoplatelet Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000007146 photocatalysis Methods 0.000 description 1
- 230000001699 photocatalysis Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G39/00—Compounds of molybdenum
- C01G39/06—Sulfides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention belongs to the technical field of enzyme preparation, and particularly relates to a preparation method of transition metal nano enzyme with fluorescence and application thereof in improving intestinal health, wherein the method comprises the following steps of mixing sodium selenite, ammonium molybdate, polyethylene glycol (PEG) and glutathione into deionized water, and mechanically stirring until a stable and dispersed solution is formed; transferring the solution into a reaction kettle, sealing the reaction kettle, placing the reaction kettle in an oven for reaction, cooling to room temperature, and filtering out the solution in the inner container of the reaction kettle; and adding absolute ethyl alcohol into the filtered solution for centrifugal separation, dialyzing for 8-12h, and drying the obtained substance in a vacuum drying oven. The preparation method is prepared by adopting a hydrothermal method, the reaction condition is mild, the operation is simple and convenient, the nano-enzyme emits blue fluorescence under 380nm excitation, the fluorescence emission peak is 460nm, the nano-enzyme has the multi-enzyme activities such as catalase activity, superoxide dismutase activity, glutathione catalase activity and the like, and the nano-enzyme has potential application value in the fields of sensing detection, enzyme-linked immunosorbent assay technology and the like.
Description
Technical Field
The invention relates to the technical field of enzyme preparation, in particular to a preparation method of transition metal nano enzyme with fluorescence and application thereof in improving intestinal health.
Background
Inflammatory Bowel Disease (IBD) refers to a range of related diseases including Crohn's Disease (CD) and Ulcerative Colitis (UC) affecting the ileum, rectum and colon. The etiology of UC is manifested as chronic, non-specific inflammation of the colon and rectum, but is relatively poorly understood, and the most frequently occurring symptoms in patients include abdominal pain, hematochezia, and intestinal leakage. In the past three decades, the incidence of UC in China has risen, emphasizing the importance of studying and treating this disease. The prevalence of UC is similar between men and women, with a bimodal distribution, with the highest peak occurring between 20 and 40 years old and the second smallest peak occurring between 60 and 70 years old. Complications including ileus, perforation or bleeding, and increased risk of bowel cancer may occur in severe UC patients. Currently, the drug treatment for UC mainly includes aminosalicylic acid, glucocorticoids, immunosuppressants and biological agents. However, many of these drugs have limited efficacy and may cause serious side effects. Many UC patients eventually experience recurrent episodes of the disease, eventually requiring surgical treatment due to poor healing and related complications. Thus, there is an urgent need to explore a new method of treating inflammatory bowel disease. Currently, one therapeutic strategy is to use nanoenzymes with excellent antioxidant properties to treat inflammation instead of traditional drugs. Nanoenzymes refer to nanomaterials having enzymatic properties. It can interfere with and regulate in vivo biocatalysis process by exerting natural enzyme-like activity, and can be used for diagnosis and prevention of various diseases. Compared with the traditional antioxidant therapeutic drugs (such as organic small molecules, vitamin derivatives and acetylcysteine), the nano-enzyme has better structural stability, is less influenced by the surrounding environment, and has higher durability of free radical scavenging activity under physiological conditions. Among them, transition metal chalcogenide materials with similar structures to graphene, with their unique physicochemical properties, become one of the most active research fields of nanoscience technology.
Transition Metal Chalcogenides (TMCs) are a class of two-dimensional (2D) materials that have been of great interest since the discovery of graphene in 2004. TMCs, generally denoted MX, consist of transition metals and chalcogenides; m is typically from groups 4-7 (Mo, W, ta, nb, re and Mn) and chalcogenides (S, se, te). The attractive force for TMCs is due to the unique optical, mechanical and electrical properties that result from their ultra-thin monolayer or multilayer atomic structure. According to reports, the transition metal halide nanomaterial has wide application prospects in the fields of catalysis, photocatalysis, biomedicine, detection, photoelectric devices, energy storage and the like. Although they have found application in biomedical applications, their use in reactive oxygen species-related diseases has been rarely reported. In particular, the potential of molybdenum-based nanoenzymes in transition metals for treating inflammatory bowel disease has not been demonstrated. Molybdenum (Mo) has been used as a nontoxic, low-cost transition metal for synthesizing various Mo-based nanomaterials having unique structural and physicochemical characteristics to obtain various properties, and has shown great potential in constructing novel nanoenzyme catalysts. The construction of the molybdenum-based nano enzyme has great significance for treating intestinal inflammation and protecting intestinal health.
Disclosure of Invention
The invention aims to provide a preparation method of transition metal nano-enzyme with fluorescence and application thereof in improving intestinal health so as to solve the technical problems in the background art.
In order to achieve the above purpose, the present invention provides the following technical solutions: a preparation method of transition metal nano enzyme with fluorescence comprises the following steps:
step 1: stirring and dispersing
Mixing sodium selenite, ammonium molybdate, polyethylene glycol and glutathione, adding into deionized water, and mechanically stirring for 50-70min until a stable dispersed solution is formed;
step 2: hydrothermal oxidation
Transferring the solution prepared in the step 1 into a reaction kettle, sealing the reaction kettle, placing the reaction kettle in a baking oven at 180-200 ℃ for reaction for 12-14h, cooling to room temperature, and filtering out the solution in the inner container of the reaction kettle;
step 3: vacuum drying
Adding absolute ethyl alcohol into the solution filtered in the step 2, centrifuging at 4200rpm for 5min, centrifuging for 3 times, dialyzing for 8-12h, drying the obtained substance in a vacuum drying oven at 70deg.C for 12h, and taking out solid to obtain fluorescent transition metal nano enzyme.
Preferably, in the step 1, the weight part ratio of the sodium selenite, the ammonium molybdate and the glutathione is 2:1:4.
Preferably, in the step 2, the reaction kettle used is a polytetrafluoroethylene lining stainless steel autoclave.
Preferably, in the step 2, PEG 6000 is adopted as polyethylene glycol, and the mass fraction of glutathione is 99%.
Preferably, the transition metal nanoenzyme with fluorescence is stored under freeze-drying conditions.
The application of the transition metal nano enzyme with fluorescence is used for improving intestinal health.
The beneficial effects of the invention are as follows: preparation method of transition metal nano enzyme with fluorescence
(1) The preparation method adopts a hydrothermal method, and has mild reaction conditions and simple and convenient operation.
(2) The nano enzyme prepared by the method emits blue fluorescence under 380nm excitation, the fluorescence emission peak is 460nm, and the nano enzyme has the multienzyme activities of catalase activity, superoxide dismutase activity, glutathione catalase activity and the like, and has potential application value in the fields of sensing detection, enzyme-linked immunosorbent assay technology and the like.
(3) The nano-enzyme prepared by the method has good biocompatibility and no toxicity.
(4) The nano-enzyme prepared by the method has stable heat resistance and cold resistance, and the freeze-dried product still has good water solubility.
(5) The nanoenzymes prepared by the method can significantly reduce clinical symptoms of DSS-induced colitis, including reduction of Disease Activity Index (DAI) scores, weight loss, colon shortening and histopathological abnormalities.
(6) The nano-enzyme prepared by the method has excellent antioxidant activity, and can reduce the capability of proinflammatory factors such as IL-1 beta, TNF-alpha, IFN-beta, IL-6 and the like at colonitis.
Drawings
FIG. 1 is an SEM image of PMNFs nanoenzyme in examples;
FIG. 2 is an XRD image of PMNFs nanoenzyme in the examples;
FIG. 3 is an XPS image of PMNFs nanoenzyme in the examples;
FIG. 4 is an image of the optical properties of PMNFs nanoenzymes in the examples;
FIG. 5 is an image of the optical properties of PMNFs nanoenzymes in the examples;
FIG. 6 is a graph of catalase-like activity of PMNFs nanoenzymes in the examples;
FIG. 7 is a graph showing data relating to a systemic toxicity test of PMNFs nanoenzymes in the examples;
FIG. 8 is a graph showing data relating to in vitro cytotoxicity experiments of PMNFs nanoenzymes in the examples;
FIG. 9 is a graph of PMNFs nanoenzyme enteritis experimental group-related data in the examples;
FIG. 10 is a graph showing data relating to antioxidant activity of PMNFs nanoenzymes in the examples;
FIG. 11 is a graph showing data relating to the anti-inflammatory response of PMNFs nanoenzymes in the examples.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Examples:
0.5g of sodium selenite, 0.25g of ammonium molybdate, 1.25g of polyethylene glycol and 1g of glutathione are mixed and added to 20ml of deionized water, and the mixture is mechanically stirred for 1 hour until a stable dispersed solution is formed. Transferring the solution into a polytetrafluoroethylene lining stainless steel autoclave, sealing the autoclave, placing the autoclave in a 200 ℃ oven for reaction for 12 hours, cooling to room temperature, and filtering out the solution in the liner. Adding absolute ethanol into the obtained solution, centrifuging at 4200rpm for 5min, centrifuging for 3 times, dialyzing for 12 hr, drying in vacuum oven at 70deg.C for 12 hr, and lyophilizing.
The nanoenzymes prepared in the examples were characterized by SEM, XRD and XPS (fig. 1-3). As shown in FIG. 1, the appearance of the nano-enzyme after preparation is sheet-shaped and the transverse dimension grain diameter is 400-2000 nanometers as can be seen by a high-resolution Scanning Electron Microscope (SEM). XRD and XPS characterization can show that the product is PEGylated Mo 3 Se 4 Nanoplatelets (PMNFs), the fluorescence excitation dependence and optical properties of the material were measured by fluorescence spectrophotometry and uv spectrophotometry, and the results are shown (fig. 4-5).
The nano-enzymes synthesized in the examples were subjected to a catalase activity test.
Using two substrates TMB and H 2 O 2 By H 2 O 2 The oxidation of TMB substrates was used as a reaction model to test the peroxidase activity of PMNFs nanoenzymes. Briefly, TMB (50 mm) 100. Mu.l, H 2 O 2 (10 mm) 100. Mu.l and PMNFs (1.6 mg/ml) 100. Mu.l were heated at 25℃for 10min. The volume of the reaction system was adjusted to 3ml using 0.1M acetic acid buffer (ph=3). In the mixed system, the absorbance of the TMB oxidation product increases with time. The catalase-like activity of PMNFs is reflected indirectly by the detection of complex formation by UV/Vis recording the change in absorbance at 652 nm. The effect of pH (2-10.0) and temperature (10-100 ℃) on catalytic oxidation was examined. The affinity of the enzyme to the substrate was assessed by measuring the Mitsunock constant (Km). Lineweaver-Burk curve was used to determine enzyme affinity. The following relationship is used:
catalase Activity and enzyme affinity see (FIG. 6)
Whole body toxicity experiments of PMNFs nanoenzymes were designed. 60 male and female half-qu mice weighing 20-22g were selected and randomly divided into 6 groups of 10 mice each. PMNFs nano-enzyme is respectively administrated according to 100mg/kg, 200 mg/kg, 400 mg/kg, and 1000mg/kg, and the control group is perfused with physiological saline with the same volume. The gastric lavage was continued for 9 days, and body weight and clinical observations were recorded daily. On day ten, the mouse anatomy was sacrificed. Evaluation was made from several aspects of body weight change, clinical observation, clinical pathology, and histopathology. As can be seen from fig. 7: body weight (FIG. 7 a) and kidney function (FIGS. 7d, e) were not significantly altered after treatment with PMNFs at different concentrations (0-1000 mg/kg). When PMNFs concentration exceeded 800mg/kg, liver function was slightly impaired (fig. 7b, c). Furthermore, the results of histological examination (fig. 7 f) showed that PMNFs resulted in hepatic cord disorders, vacuolation and hepatocyte pellet degeneration in the 800 and 1000mg/kg PMNFs treated groups.
In vitro cytotoxicity experiments of PMNFs nanoenzymes were designed. Cytotoxicity experiments Using RAW264.7 macrophages from mice as a model, 7 macrophages were cultured in DMEM (Gibco BRL, new York Gellan island) containing 10% fetal bovine serum and penicillin-streptomycin antibiotics (50. Mu.g/ml) and thenAt 37℃and 5% CO 2 Culturing in an incubator under the condition until the cells adhere to the wall and spread on the bottom of the culture dish. The PMNFs nanoenzyme solutions were separately sterilized at different concentrations (0-16 mg/kg) and dissolved in culture medium to be incubated with the cells for 24h, and the relative activities of the cells were determined using the standard MTT method. The data are shown (FIG. 8 a), where PMNFs show no significant toxic effect on cells, and up to 1mg/kg. In addition, lipopolysaccharide (LPS) treated (1. Mu.g/ml, 4 h) RAW264.7 macrophages were designed with/without different PMNFs (0-1 mg/ml,1 h) pretreatment to observe the change in NO concentration. As shown in the results (fig. 8 b), the positive control group LPS macrophages showed significantly higher NO concentration in vivo than the material group, which remained almost identical to the blank.
The application of PMNFs nano-enzyme in improving intestinal health is that a DSS induced enteritis model of mice is designed, and PMNFs with the concentration of 100mg/kg is selected for gastric lavage administration treatment.
Table 1: experimental grouping information
Grouping information is shown in Table 1, and 15 mice per group were adapted for three days. The feed is normally fed, cold drink water is placed after boiling, then the 1 st group continuously drinks and boils freely, the 2-3 groups are replaced by drinking water with 3% DSS concentration, and each group is fed by stomach irrigation every day according to the scheme in the table 1, 1 time every day and is normally fed for 9 days. Mice were weighed daily and monitored for clinical signs of colitis (e.g., weight loss, fecal consistency, and rectal bleeding). The colitis Disease Activity Index (DAI) of each mouse was calculated daily based on the criteria of weight loss from baseline (0, no weight loss; 1-3% weight loss; 2, 3-6% weight loss; 3, 6-9% weight loss; 4, >9% weight loss); stool consistency (0, normal, 2, constipation, 4, diarrhea), fecal blood (0, none, 2, large visible blood; 4, severe bleeding). Macroscopic bleeding is defined as fresh perianal blood with obvious hematochezia, and the condition of blood and stool of the mice can be observed about 3-4 days. On day 10, anesthetized mice were collected whole blood. Thereafter, the colon was resected, its length measured, and a portion thereof was stored at-80 ℃ for subsequent analysis, and the remaining tissue was fixed in 4% paraformaldehyde for HE staining microscopy. Pathological diagnosis is carried out and scoring is carried out. The histopathological features evaluated include acute and/or chronic inflammation, proliferative changes in the colonic epithelium, crypt distortion or damage, fibrosis and tumors. Three independent parameters, inflammatory cell infiltration, proliferation degree and crypt damage were measured. The three independent scores were added up to 12 points and the total histological score was calculated. Inflammation assessment using literature scoring system: 0 = no inflammation; 1 = mild chronic mucosal inflammation; 2 = mild acute or moderate chronic mucosal and submucosal inflammation; 3 = severe acute or chronic mucosal, submucosal, transmural inflammation. The proliferative change was scored as an increase in crypt epithelial cell number relative to baseline epithelial cell number per crypt as follows, 0 = none or minimal (< 20%); 1 = mild (21-35%); 2 = gentle (36-50%); 3= (> 50%). Cellar injury score 0 = none; 1 = surface epithelium only damaged; 2 = damaged surface crypt and epithelial cells; 3 = loss of the entire crypt, damaged surface epithelium; 4 = loss of the entire crypt and epithelium. MPO is a glycosylase found in neutrophil and monocyte particles and is a biomarker for assessing disease status in IBD patients. Thus, neutrophil infiltration into inflamed tissue can be assessed by measuring MPO activity.
The results show that DSS mice significantly reduced weight loss and colon length, and increased DAI and histopathological scores, compared to the control group. As shown (fig. 9), the weight loss on day 10 was significantly reduced in the dss+pmnfs treated group compared to the DSS treated group (fig. 9 a). Furthermore, DSS-induced loss of DAI and colon length was significantly reduced by treatment with PMNFs (fig. 9b, c). In pathological sections, it can be observed that the intestinal damage of the positive group is larger, the intestinal damage of the negative group is basically absent, the material treatment group has a certain effect on the recovery of enteritis, and after PMNFs combined treatment, the activity of colon MPO is obviously reduced (figure 9 d), which shows that the treatment with PMNFs can inhibit neutrophil infiltration in inflammatory colon. Furthermore, administration of PMNFs significantly reduced the histological signs of colitis, including tissue damage and inflammatory infiltrates, including reduced tissue damage and inflammatory infiltrates (fig. 9e, f).
The antioxidant activity of PMNFs was determined. Intracellular ROS content was detected using DCFH-DA (M36008, invitrogen). Colonic frozen sections DCFH-DA staining detects ROS within the colon. Colon sections were incubated with 20 μm DCFH-DA for 20min and all images were acquired under fluorescence microscopy. RAW264.7 cells were blanket cultured in 96-well plates for 24h. LPS treatment (1. Mu.g/ml, 6 h) RAW264.7 macrophages with/without different PMNFs (1 mg/ml,4 h) pretreatment. The PBS buffer was washed twice and the washed cells were incubated with 20. Mu.M DCFH-DA for 20 minutes. The cells were then rinsed twice with PBS and fluorescence intensity was measured using a Synergy 2 multi-mode plate reader (BioTek Instruments). Simultaneously, ROS, MDA, T-aoc, CAT, GSH-px, SOD and GSH levels in the colon were measured with the test kit, and the Nrf2-KEAP1 signaling pathway was measured to reveal the underlying blood molecular mechanism of MoSe2 antioxidant effect. . The results show that PMNFs significantly inhibited LPS-induced ROS in RAW264.7 macrophages (fig. 10 a). Furthermore, PMNFs can significantly reduce colonic DSS induced MDA levels (fig. 10 b). PMNFs can rescue antioxidant capacity such as T-aoc, CAT, GSH-px, SOD activity, and GSH levels (fig. 10 c). An increase in KEAP1 protein level and a decrease in Nrf2 protein level indicated that the Nrf2-KEAP1 signaling pathway was inhibited in DSS-induced colitis mice (fig. 10 d). The Nrf2-KEAP1 signal path is activated by MOS2 therapy. Also, PMNFs treatment significantly increased the RNA levels of antioxidant enzymes (CuZn-SOD, mn-SOD, cata and GSH-Px) compared to DSS group (FIG. 10 e)
The effect of PMNFs administration on DSS-induced inflammatory responses was evaluated. The levels of the pro-inflammatory cytokines IL-1 beta, IL-6, TNF-alpha and IFN-beta in both serum and colon were measured simultaneously by enzyme-linked immunosorbent assay (ELISA). qRT-PCR was used to detect mRNA expression of the pro-inflammatory cytokines IL-1 beta, IL-6, TNF-alpha and IFN-beta in the colon, western blot (Western blot) analysis was used to detect significant differences in TLR4, p-NF- κB and IκB protein expression in the colon, and to quantitatively detect the densities of TLR4, p-NF- κB and IκB/actin ratios. DSS resulted in significant elevation of serum and colonic IL-1 beta, IL-6, TNF-alpha and IFN-beta levels compared to the control group (fig. 11a, b). In contrast, the addition of PMNFs can significantly reverse this trend. In agreement therewith, simultaneously, the protein levels and mRNA expression of the pro-inflammatory factors (IL-1β, IL-6, TNF- α and IFN- β) were significantly reduced in the dss+pmnfs group compared to the DSS treated group (fig. 11 c). DSS-induced colitis mice have elevated levels of TLR4 and p-NF- κb protein and decreased levels of ikb protein, suggesting that TLR4/nfκb pathways are activated. Whereas co-treatment of PMNFs reversed DSS-induced activation of the TLR 4/NF-. Kappa.B pathway (FIG. 11 d).
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (6)
1. A preparation method of a transition metal nano enzyme with fluorescence is characterized in that: the method comprises the following steps:
step 1: stirring and dispersing
Mixing sodium selenite, ammonium molybdate, polyethylene glycol and glutathione, adding into deionized water, and mechanically stirring for 50-70min until a stable dispersed solution is formed;
step 2: hydrothermal oxidation
Transferring the solution prepared in the step 1 into a reaction kettle, sealing the reaction kettle, placing the reaction kettle in a baking oven at 180-200 ℃ for reaction for 12-14h, cooling to room temperature, and filtering out the solution in the inner container of the reaction kettle;
step 3: vacuum drying
Adding absolute ethyl alcohol into the solution filtered in the step 2, centrifuging at 4200rpm for 5min, centrifuging for 3 times, dialyzing for 8-12h, drying the obtained substance in a vacuum drying oven at 70deg.C for 12h, and taking out solid to obtain fluorescent transition metal nano enzyme.
2. The method for preparing the fluorescent transition metal nano-enzyme according to claim 1, which is characterized in that: in the step 1, the weight part ratio of sodium selenite, ammonium molybdate, polyethylene glycol and glutathione is 2:1:5:4.
3. The method for preparing the fluorescent transition metal nano-enzyme according to claim 1, which is characterized in that: in step 2, the reaction vessel used was a polytetrafluoroethylene-lined stainless steel autoclave.
4. The method for preparing the fluorescent transition metal nano-enzyme according to claim 2, which is characterized in that: in the step 2, PEG 6000 is adopted as polyethylene glycol, and the mass fraction of glutathione is 99%.
5. The method for preparing the fluorescent transition metal nano-enzyme according to claim 1, which is characterized in that: the transition metal nano enzyme with fluorescence is stored under the freeze drying condition.
6. An application of a transition metal nano enzyme with fluorescence, which is characterized in that: the application of the fluorescent transition metal nano enzyme improves intestinal health.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310083669.0A CN116139271A (en) | 2023-02-08 | 2023-02-08 | Preparation method of transition metal nano enzyme with fluorescence and application of transition metal nano enzyme in improving intestinal health |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310083669.0A CN116139271A (en) | 2023-02-08 | 2023-02-08 | Preparation method of transition metal nano enzyme with fluorescence and application of transition metal nano enzyme in improving intestinal health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116139271A true CN116139271A (en) | 2023-05-23 |
Family
ID=86352219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310083669.0A Pending CN116139271A (en) | 2023-02-08 | 2023-02-08 | Preparation method of transition metal nano enzyme with fluorescence and application of transition metal nano enzyme in improving intestinal health |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116139271A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116874556A (en) * | 2023-06-01 | 2023-10-13 | 四川农业大学 | Preparation method and application of selenium glutathione nano-enzyme with antioxidant activity |
-
2023
- 2023-02-08 CN CN202310083669.0A patent/CN116139271A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| HONGRUI GUO等: "Mo3Se4 nanoparticle with ROS scavenging and multi-enzyme activity for the treatment of DSS-induced colitis in mice", REDOX BIOLOGY, vol. 56, 14 August 2022 (2022-08-14), pages 6 - 7 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116874556A (en) * | 2023-06-01 | 2023-10-13 | 四川农业大学 | Preparation method and application of selenium glutathione nano-enzyme with antioxidant activity |
| CN116874556B (en) * | 2023-06-01 | 2024-10-29 | 四川农业大学 | Preparation method and application of selenium glutathione nano-enzyme with antioxidant activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vong et al. | An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice | |
| Zhang et al. | Acute toxicity study of the interaction between titanium dioxide nanoparticles and lead acetate in mice | |
| Sha et al. | Suppression of NSAID-induced small intestinal inflammation by orally administered redox nanoparticles | |
| Wang et al. | Polyoxometalate nanoclusters: a potential preventative and therapeutic drug for inflammatory bowel disease | |
| Mao et al. | GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease | |
| Dong et al. | Carbon dots nanozyme for anti-inflammatory therapy via scavenging intracellular reactive oxygen species | |
| Zhang et al. | An olsalazine nanoneedle-embedded inulin hydrogel reshapes intestinal homeostasis in inflammatory bowel disease | |
| Gao et al. | Hyaluronic acid/serotonin-decorated cerium dioxide nanomedicine for targeted treatment of ulcerative colitis | |
| CN116139271A (en) | Preparation method of transition metal nano enzyme with fluorescence and application of transition metal nano enzyme in improving intestinal health | |
| Sun et al. | Gram-scale preparation of quercetin supramolecular nanoribbons for intestinal inflammatory diseases by oral administration | |
| Albashari et al. | Local Spinal Cord Injury Treatment Using a Dental Pulp Stem Cell Encapsulated H2S Releasing Multifunctional Injectable Hydrogel | |
| Zhang et al. | Programmed pH-responsive core–shell nanoparticles for precisely targeted therapy of ulcerative colitis | |
| Wang et al. | Mitochondria-targeting folic acid-modified nanoplatform based on mesoporous carbon and a bioactive peptide for improved colorectal cancer treatment | |
| Li et al. | Preparation, physical characterization, pharmacokinetics and anti-hyperglycemic activity of esculetin-loaded mixed micelles | |
| Pourmadadi et al. | A green approach for preparation of polyacrylic acid/starch incorporated with titanium dioxide nanocomposite as a biocompatible platform for curcumin delivery to breast cancer cells | |
| Wang et al. | Facile in situ synthesis of ultrasmall near-infrared-emitting gold glyconanoparticles with enhanced cellular uptake and tumor targeting | |
| Setyaningsih et al. | Antihyperglycemic activity of Porphyridium cruentum biomass and extra-cellular polysaccharide in streptozotocin-induced diabetic rats | |
| CN115068629B (en) | Drug-loaded nanoparticle based on curcumin and cerium oxide as well as preparation method and application thereof | |
| Zhong et al. | AgAu-modified quasi-MIL-53 hybrid nanozymes with triple enzyme-like activities for boosting biocatalytic disinfection | |
| Zhao et al. | Reactive oxygen species-responsive polyether micelle nanomaterials for targeted treatment of ulcerative colitis | |
| Li et al. | Effect of neutrophil-like melanin biomimic photothermal nanoparticles on glomerular mesangial cells in rats with gestational diabetic nephropathy | |
| Feng et al. | Polydopamine‐Mediated Metal–Organic Frameworks Modification for Improved Biocompatibility | |
| CN114129508A (en) | Combined material based on metal nano-enzyme material and temperature sensitive gel and construction method thereof | |
| CN109224083B (en) | Application of poloxamer-modified iron oxide nanoparticles in preparation of drugs for treating non-alcoholic fatty liver diseases | |
| Zhang et al. | Synthesis and evaluation of targeted nanomicelle delivery system with rhein as the hydrophobic end and its synergistic therapy effect on tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |